Caris Life Sciences (CAI) Net Income towards Common Stockholders (2024 - 2026)

Caris Life Sciences' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 99.6% year-over-year to -$510000.0; the TTM figure through Mar 2026 stood at -$411.4 million (down 10.85% YoY), while the FY2025 annual figure was -$538.0 million, down 42.22% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$510000.0, down from $82.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $82.0 million in Q4 2025, with the low at -$517.2 million in Q2 2025.
• The 3-year median for Net Income towards Common Stockholders is -$75.9 million (2024), against an average of -$97.8 million.
• Peak annual rise in Net Income towards Common Stockholders reached 232.3% in 2025, while the deepest fall reached 476.07% in 2025.
• Caris Life Sciences' Net Income towards Common Stockholders stood at -$61.9 million in 2024, then jumped by 232.3% to $82.0 million in 2025, then plunged by 100.62% to -$510000.0 in 2026.
• Business Quant data shows CAI's Net Income towards Common Stockholders at -$510000.0 in Q1 2026, $82.0 million in Q4 2025, and $24.3 million in Q3 2025.